The popularity of copyright’s blockbuster initially drove a surge for major pharmaceutical companies, however recent shifts present a complicated picture for shareholders. Off-patent versions are eroding profits, and continued legal battles add more complexity to the equation. While certain companies could still gain from complementary products,